Piramal Pharma [PPLPHARMA] vs Cipla [CIPLA] Detailed Stock Comparison
Piramal Pharma
NSE
Loading...
Cipla
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Piramal Pharma wins in 5 metrics, Cipla wins in 14 metrics, with 0 ties. Cipla appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Piramal Pharma | Cipla | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 263.99 | 22.27 | Cipla |
| Price-to-Book Ratio | 3.10 | 3.85 | Piramal Pharma |
| Debt-to-Equity Ratio | 59.77 | 1.40 | Cipla |
| PEG Ratio | 0.67 | 23.38 | Piramal Pharma |
| EV/EBITDA | 23.22 | 15.50 | Cipla |
| Profit Margin (TTM) | 1.07% | 19.62% | Cipla |
| Operating Margin (TTM) | -4.68% | 22.31% | Cipla |
| EBITDA Margin (TTM) | N/A | 22.31% | N/A |
| Return on Equity | 1.12% | 16.85% | Cipla |
| Return on Assets (TTM) | 0.58% | 14.10% | Cipla |
| Free Cash Flow (TTM) | $2.28B | $34.57B | Cipla |
| Dividend Yield | 0.07% | 1.72% | Cipla |
| 1-Year Return | 4.32% | 5.70% | Cipla |
| Price-to-Sales Ratio (TTM) | 2.75 | 4.37 | Piramal Pharma |
| Enterprise Value | $296.20B | $1,099.34B | Cipla |
| EV/Revenue Ratio | 3.24 | 4.00 | Piramal Pharma |
| Gross Profit Margin (TTM) | 64.11% | 68.25% | Cipla |
| Revenue per Share (TTM) | $69 | $340 | Cipla |
| Earnings per Share (Diluted) | $0.72 | $66.71 | Cipla |
| Beta (Stock Volatility) | 0.06 | 0.10 | Piramal Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Piramal Pharma vs Cipla Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Piramal Pharma | 1.44% | -2.13% | -8.88% | -10.66% | -5.41% | -26.66% |
| Cipla | 2.49% | 1.45% | 2.53% | 0.66% | 5.00% | 2.85% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Piramal Pharma | 4.32% | 10.75% | 10.75% | 10.75% | 10.75% | 10.75% |
| Cipla | 5.70% | 47.71% | 100.01% | 118.18% | 390.52% | 991.54% |
Performance & Financial Health Analysis: Piramal Pharma vs Cipla
| Metric | PPLPHARMA | CIPLA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹251.21B | ₹1.20T |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 5,716,341 | 1,677,051 |
| 90 Day Avg. Volume | 5,381,655 | 1,586,403 |
| Last Close | ₹192.13 | ₹1,560.00 |
| 52 Week Range | ₹181.50 - ₹307.90 | ₹1,335.00 - ₹1,579.90 |
| % from 52W High | -37.60% | -1.26% |
| All-Time High | ₹307.90 (Nov 04, 2024) | ₹1,577.00 (Jul 28, 2025) |
| % from All-Time High | -37.60% | -1.08% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.03% |
| Quarterly Earnings Growth | -0.01% | 0.10% |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | 0.20% |
| Operating Margin (TTM) | -0.05% | 0.22% |
| Return on Equity (TTM) | 0.01% | 0.17% |
| Debt to Equity (MRQ) | 59.77 | 1.40 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹61.35 | ₹386.24 |
| Cash per Share (MRQ) | ₹3.09 | ₹131.44 |
| Operating Cash Flow (TTM) | ₹2.44B | ₹55.16B |
| Levered Free Cash Flow (TTM) | ₹911.30M | ₹52.73B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.07% | 1.72% |
| Last 12-Month Dividend | ₹0.14 | ₹26.00 |
Valuation & Enterprise Metrics Analysis: Piramal Pharma vs Cipla
| Metric | PPLPHARMA | CIPLA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 263.99 | 22.27 |
| Forward P/E | 43.19 | 23.38 |
| PEG Ratio | 0.67 | 23.38 |
| Price to Sales (TTM) | 2.75 | 4.37 |
| Price to Book (MRQ) | 3.10 | 3.85 |
| Market Capitalization | ||
| Market Capitalization | ₹251.21B | ₹1.20T |
| Enterprise Value | ₹296.20B | ₹1.10T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.24 | 4.00 |
| Enterprise to EBITDA | 23.22 | 15.50 |
| Risk & Other Metrics | ||
| Beta | 0.06 | 0.10 |
| Book Value per Share (MRQ) | ₹61.35 | ₹386.24 |
Financial Statements Comparison: Piramal Pharma vs Cipla
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PPLPHARMA | CIPLA |
|---|---|---|
| Revenue/Sales | ₹19.34B | ₹68.37B |
| Cost of Goods Sold | ₹6.94B | ₹21.71B |
| Gross Profit | ₹12.40B | ₹46.66B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-905.80M | ₹15.25B |
| EBITDA | ₹1.84B | ₹20.37B |
| Pre-Tax Income | ₹-790.20M | ₹17.70B |
| Income Tax | ₹26.80M | ₹4.78B |
| Net Income (Profit) | ₹-817.00M | ₹12.92B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PPLPHARMA | CIPLA |
|---|---|---|
| Cash & Equivalents | ₹3.69B | ₹5.89B |
| Total Current Assets | ₹57.97B | ₹232.89B |
| Total Current Liabilities | ₹37.66B | ₹54.84B |
| Long-Term Debt | ₹33.13B | ₹2.52B |
| Total Shareholders Equity | ₹81.25B | ₹312.89B |
| Retained Earnings | ₹10.49B | ₹256.44B |
| Property, Plant & Equipment | ₹250.60M | ₹52.62B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PPLPHARMA | CIPLA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PPLPHARMA | CIPLA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,716,341 | 1,677,051 |
| Average Daily Volume (90 Day) | 5,381,655 | 1,586,403 |
| Shares Outstanding | 1.32B | 807.62M |
| Float Shares | 608.08M | 562.88M |
| % Held by Insiders | 0.55% | 0.31% |
| % Held by Institutions | 0.20% | 0.38% |
Dividend Analysis & Yield Comparison: Piramal Pharma vs Cipla
| Metric | PPLPHARMA | CIPLA |
|---|---|---|
| Last 12-Month Dividend | ₹0.14 | ₹26.00 |
| Last 12-Month Dividend Yield | 0.07% | 1.72% |
| 3-Year Avg Annual Dividend | ₹0.08 | ₹16.00 |
| 3-Year Avg Dividend Yield | 0.07% | 0.76% |
| 3-Year Total Dividends | ₹0.25 | ₹48.00 |
| Ex-Dividend Date | Jul 16, 2025 | Jun 27, 2025 |